Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$2.19B |
| 2 |
GE Vernova
GEV
|
+$1.16B |
| 3 |
Meta Platforms (Facebook)
META
|
+$501M |
| 4 |
Palantir
PLTR
|
+$451M |
| 5 |
DoorDash
DASH
|
+$411M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.22B |
| 2 |
Ascendis Pharma A/S
ASND
|
+$866M |
| 3 |
Applovin
APP
|
+$690M |
| 4 |
DAY
Dayforce
DAY
|
+$576M |
| 5 |
Workday
WDAY
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.5% |
| 2 | Healthcare | 20.49% |
| 3 | Industrials | 11.17% |
| 4 | Consumer Discretionary | 9.27% |
| 5 | Communication Services | 8.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
iShares MSCI Emerging Markets ex China ETF
EMXC
$23.4B
| $68.5M | 0.03% |
+870,965
| New | +$70M |
|
|
DFTX
352
Definium Therapeutics
DFTX
$5.73B
| $67.2M | 0.03% |
3,556,041
+1,144,345
| +47% | +$19.4M |
|
|
SPYM
353
State Street SPDR Portfolio S&P 500 ETF
SPYM
$158B
| $66.8M | 0.03% |
872,415
-62,735
| -7% | -$5.02M |
|
|
BCAX
354
Bicara Therapeutics
BCAX
$1.78B
| $66.4M | 0.03% |
3,339,218
+692,933
| +26% | +$11.9M |
|
355
Public Storage
PSA
$60.2B
| $65M | 0.03% |
239,768
-19,046
| -7% | -$5.46M |
|
356
ATS Corp
ATS
$2.56B
| $64.5M | 0.03% |
2,297,214
+1,435,375
| +167% | +$43.2M |
|
357
Frontdoor
FTDR
$5.02B
| $64.5M | 0.03% |
1,220,768
+317,995
| +35% | +$19M |
|
358
MoonLake Immunotherapeutics
MLTX
$1.59B
| $64.3M | 0.03% |
3,451,628
+1,355,640
| +65% | +$22.5M |
|
359
TechnipFMC
FTI
$30.6B
| $64M | 0.03% |
924,838
+205,637
| +29% | +$12.4M |
|
360
Kirby Corp
KEX
$7.95B
| $63.8M | 0.03% |
480,015
-78,285
| -14% | -$9.92M |
|
361
New York Times
NYT
$11.6B
| $63.7M | 0.03% |
761,118
+177,045
| +30% | +$13.4M |
|
362
iShares Core MSCI Emerging Markets ETF
IEMG
$149B
| $63.7M | 0.03% |
+912,578
| New | +$65.9M |
|
363
Simon Property Group
SPG
$74.5B
| $63.2M | 0.03% |
338,772
+285,426
| +535% | +$54.4M |
|
364
Blue Bird Corp
BLBD
$2.41B
| $62.7M | 0.03% |
1,102,335
+324,710
| +42% | +$17.5M |
|
365
Crane Co
CR
$13.1B
| $61.8M | 0.03% |
361,270
+71,086
| +24% | +$13.6M |
|
366
Andersons Inc
ANDE
$2.65B
| $61.8M | 0.03% |
860,942
+223,600
| +35% | +$14.4M |
|
367
Neurocrine Biosciences
NBIX
$17.7B
| $61.5M | 0.03% |
466,977
+7,801
| +2% | +$1.04M |
|
|
DMRA
368
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.77B
| $61.4M | 0.03% |
2,362,696
+2,360,957
| +135,765% | +$60.7M |
|
369
Lazard
LAZ
$4.37B
| $60.8M | 0.03% |
1,431,358
+48,607
| +4% | +$2.38M |
|
370
Alkami Technology
ALKT
$1.8B
| $60.4M | 0.03% |
3,855,334
+646,898
| +20% | +$11.9M |
|
371
Collegium Pharmaceutical
COLL
$1.14B
| $60.4M | 0.03% |
1,825,651
+377,073
| +26% | +$16M |
|
372
Blackbaud
BLKB
$1.5B
| $60.1M | 0.03% |
1,555,833
+58,806
| +4% | +$2.94M |
|
373
Delta Air Lines
DAL
$55.9B
| $60.1M | 0.03% |
903,471
-185,935
| -17% | -$12.5M |
|
374
Medpace
MEDP
$16.8B
| $60M | 0.03% |
124,954
+21,709
| +21% | +$11.1M |
|
375
Erasca
ERAS
$6.63B
| $60M | 0.03% |
+3,710,966
| New | +$43.9M |
|
Similar funds
Janus Henderson Group's Q1 2026 Portfolio in Review
As of Q1 2026, Janus Henderson Group held 2,488 positions worth $209B, down 6.2% from $223B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Janus Henderson Group's Q1 2026 filing shows 82 new, 739 increased, 627 reduced and 81 closed positions. Its largest new stake was Forgent Power Solutions: 7,769,612 shares worth $227M. The largest sale was Microsoft, an estimated $1.22B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 35% a quarter earlier, followed by Healthcare and Industrials.
- Janus Henderson Group's largest Q1 2026 buy was Forgent Power Solutions: 7,769,612 shares worth $227M.
- Janus Henderson Group added most to AstraZeneca in Q1 2026, an estimated $2.19B increase.
- Janus Henderson Group's biggest Q1 2026 reduction was Microsoft, cutting an estimated $1.22B.
- Janus Henderson Group fully exited Ascendis Pharma A/S in Q1 2026, selling an estimated $866M.
- Janus Henderson Group's ten largest holdings make up 30% of its $209B portfolio in Q1 2026.
- Janus Henderson Group opened 82 new positions and closed 81 in Q1 2026.
- Janus Henderson Group's portfolio value fell 6.2% quarter-over-quarter to $209B.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.